{"entity":{"id":"courtney-dinardo","kind":"person","name":"Courtney D. DiNardo","aka":[],"tldr":"Led VIALE-A, which made venetoclax plus azacitidine the standard for older patients with acute myeloid leukaemia.","summary":"Courtney DiNardo was principal investigator of VIALE-A, which showed venetoclax plus azacitidine improves survival and doubles remission rates in older adults with AML unfit for intensive chemotherapy, replacing hypomethylating agents alone and reshaping AML treatment globally. She led the first-in-human ivosidenib trial and co-led AGILE (ivosidenib plus azacitidine in IDH1-mutant AML). Her work continues on venetoclax-based triplets and measurable residual disease.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=DiNardo%20CD%5BAuthor%5D%20venetoclax%20azacitidine"}],"tags":["aml","venetoclax","trialist"],"related":[],"cancers":["aml"],"sections":[],"technologies":[],"targets":["bcl2","idh"],"drugs":["venetoclax"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["viale-a","agile"],"people":[],"bottlenecks":[],"keyPapers":["paper-viale-a-venetoclax-azacitidine-nejm-2020","paper-agile-ivosidenib-azacitidine-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Leukemia, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Acute myeloid leukaemia","Venetoclax combinations","IDH inhibitors","Older patients"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=DiNardo%20CD%5BAuthor%5D%20venetoclax%20azacitidine"}],"papers":[{"title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia (VIALE-A)","journal":"NEJM","year":2020,"doi":"10.1056/NEJMoa2012971"},{"title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","journal":"NEJM","year":2018,"doi":"10.1056/NEJMoa1716984"},{"title":"AGILE: ivosidenib plus azacitidine for newly diagnosed IDH1-mutated AML in patients unfit for intensive chemotherapy","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2117344","doi":"10.1056/NEJMoa2117344"}],"orcid":"0000-0001-9003-0390"},"route":"/people/courtney-dinardo/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"target":[{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/"},{"id":"idh","kind":"target","name":"IDH1 / IDH2","route":"/targets/idh/"}],"drug":[{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"institution":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"}],"trial":[{"id":"agile","kind":"trial","name":"AGILE","route":"/trials/agile/"},{"id":"viale-a","kind":"trial","name":"VIALE-A","route":"/trials/viale-a/"}],"paper":[{"id":"paper-agile-ivosidenib-azacitidine-nejm-2022","kind":"paper","name":"AGILE: ivosidenib plus azacitidine for newly diagnosed IDH1-mutated AML in patients unfit for intensive chemotherapy","route":"/key-papers/paper-agile-ivosidenib-azacitidine-nejm-2022/"},{"id":"paper-viale-a-venetoclax-azacitidine-nejm-2020","kind":"paper","name":"VIALE-A: venetoclax plus azacitidine for older adults with acute myeloid leukaemia who cannot have intensive chemotherapy","route":"/key-papers/paper-viale-a-venetoclax-azacitidine-nejm-2020/"}],"roadmap":[{"id":"epigenetics-roadmap","kind":"roadmap","name":"Epigenetic therapy roadmap: loosening silenced genes → mutation-specific enzymes → editing the epigenome","route":"/roadmaps/epigenetics-roadmap/"}]}}